FDA Grants De Novo Classification to TytoCare’s AI Otoscopy Tool

The AI-driven software analyzes otoscopy videos to detect eardrum bulging, establishing a new regulatory category for ENT diagnostic aids. TytoCare has received FDA De Novo classification for its Tyto Insights for ENT Suite, an artificial intelligence-powered solution for analyzing otoscopy videos....

✦ Clinical Takeaway ✦

Clinicians should note this regulatory milestone as the first FDA-cleared AI otoscopy video analysis tool for eardrum bulging detection, but evidence of clinical accuracy and workflow impact in audiology settings is not yet established from this announcement alone.

✦ Why It Matters ✦

This FDA De Novo classification establishes a new regulatory pathway for AI-driven ENT diagnostics, potentially accelerating the adoption of remote or AI-assisted otoscopy in hearing and primary care settings.

✦ Key Points ✦

01FDA granted De Novo classification to TytoCare's Tyto Insights for ENT Suite.
02

Live dispatches

FDA Grants De Novo Classification to TytoCare’s AI Otoscopy Tool

Ep. 2022-10 FDA Final Rule on OTC Hearing Aids Series, Part 1: An Overview of OTC Devices With Victor Bray, PhD, and David Akbari, AuD

FDA Approves Regeneron's Otarmeni, First Gene Therapy for Genetic Hearing Loss

Ep. 2022-10 FDA Final Rule on OTC Hearing Aids Series, Part 3: The Outlook Among the Obstacles With Stephanie Czuhajewski, MPH, CFE

Ep. 2022-10 FDA Final Rule on OTC Hearing Aids Series, Part 2: The New Category of Prescription Hearing Aids With Alicia Spoor, AuD

Ep. 2022-10 FDA Final Rule on OTC Hearing Aids Series, Part 4: A Call to Action With Kristin Davis, AuD

The Non-Compete Agreement Faces An Uncertain Future

Australian-developed Earflo cup receives FDA Clearance for otitis media

Our Friends from the Hearing Industries Association Talk Hearing Aid Trends, Surveys and Advocacy